Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 5/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31104367 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRPRKDCKCNJ1LMNA | |
| SCHEMBL26050997 | 0.83 | KCNJ1 (0.36) | ALDH1A1TSHRPRKDCKCNJ1LMNA | |
| SCHEMBL898807 | 0.80 | TDP1 (0.36) | ALDH1A1TSHRPRKDCKCNJ1LMNA | |
| SCHEMBL29390677 | 0.80 | TDP1 (0.36) | ALDH1A1TSHRPRKDCKCNJ1LMNA | |
| SCHEMBL6015132 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TSHRPRKDCKCNJ1LMNA | |
| SCHEMBL584614 | 0.78 | ERN1 (0.42) | ALDH1A1TSHRKCNJ1LMNAMEN1 | |
| SCHEMBL6438818 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TSHRKCNJ1LMNAMEN1 | |
| SCHEMBL30065195 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TSHRPRKDCKCNJ1LMNA | |
| SCHEMBL19641559 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TSHRPRKDCKCNJ1LMNA | |
| SCHEMBL25250329 | 0.75 | ERN1 (0.39) | ALDH1A1TSHRPRKDCLMNAERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2024182693-A1 | 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | VIVIDION THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | disclosed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3625228-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| CN-110612299-A | Pyrimidine derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018210988-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ALDH1A1 468/4885TSHR 654/4885PRKDC 4809/4885 |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | ALDH1A1 468/4885TSHR 654/4885PRKDC 4809/4885 |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | ALDH1A1 2652/4885TSHR 1618/4885PRKDC 2817/4885 |
| US-20180044302-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | GBA1, UGCG, GBA2 | ALDH1A1 1342/4885TSHR 3371/4885PRKDC 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.